BCL2 and cancer: The most successful of these drugs is the BCL-2 inhibitor venetoclax, which is approved for the treatment of chronic lymphocytic leukemia (CLL) [2, 3] and has shown considerable activity in therapy for other cancers, such as acute myeloid leukemia (AML) [4].